Feb 9 |
Catalent Non-GAAP EPS of -$0.24 misses by $0.22, revenue of $1.03B beats by $20M
|
Feb 9 |
Catalent, Inc. Reports Second Quarter Fiscal 2024 Results
|
Feb 8 |
Catalent Q2 2024 Earnings Preview
|
Feb 8 |
UPDATE 2-Astrazeneca says Catalent deal shows need for in-house capacity
|
Feb 8 |
Astrazeneca says Catalent deal shows need for in-house capacity
|
Feb 7 |
EU drug regulators to assess potential impact of Catalent-Novo merger
|
Feb 7 |
Catalent - Novo Holdings Merger: Attractive Spread
|
Feb 7 |
UPDATE 1-US FDA finds control lapses at Catalent plant being sold to Novo
|
Feb 7 |
UPDATE 2-EU watchdog looking into impact on drug availability from Catalent-Novo deal
|
Feb 7 |
Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings
|